The primary outcome occurred in 21 % of patients receiving dexamethasone versus 28 % of patients not receiving dexamethasone , and this was not statistically significant when adjusting for stratification variables originally used in the PROXI trial [ OR 0.90 , 95 % CI ( 0.65-1 .24 ) ] .